Details of the Drug Combination

General Information of Drug Combination (ID: DCMYYA0)

Drug Combination Name
Lithium Carbonate Valproic Acid
Indication
Disease Entry Status REF
Bipolar Disorder Phase 1 [1]
Component Drugs Lithium Carbonate   DMR1WBZ Valproic Acid   DMS49KH
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

References

1 ClinicalTrials.gov (NCT00221975) Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Valproic Acid FDA Label
4 Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid. Med Hypotheses. 2020 May 27;143:109891.